Table III.

Chronic adverse events that developed after 6 months of treatment.

		Grade
Adverse event	n	0	1	2	3	4
Genitourinary, n (%)						0 (0)
Frequency	65	37 (57.0)	26 (40.0)	1 (1.5)	1 (1.5)	0 (0)
Urgency	65	38 (58.5)	26 (40.0)	1 (1.5)	0 (0)	0 (0)
Urethral pain	65	50 (76.9)	14 (21.6)	1 (1.5)	0 (0)	0 (0)
Retention	65	57 (87.7)	6 (9.2)	2 (3.1)	0 (0)	0 (0)
Urinary incontinence	65	45 (69.2)	14 (21.6)	6 (9.2)	0 (0)	0 (0)
Hematuria	65	62 (95.4)	2 (3.1)	1 (1.5)	0 (0)	0 (0)
Urinary tract obstruction	65	60 (92.3)	0 (0)	4 (6.2)	1 (1.5)	0 (0)
Cystitis non-infective	65	65 (100)	0 (0)	0 (0)	0 (0)	0 (0)
Gastrointestinal, n (%)
Diarrhea	65	65 (100)	0 (0)	0 (0)	0 (0)	0 (0)
Rectal hemorrhage	65	63 (96.9)	2 (3.1)	0 (0)	0 (0)	0 (0)
Proctitis	65	63 (96.9)	2 (3.1)	0 (0)	0 (0)	0 (0)
Rectal pain	65	65 (100)	0 (0)	0 (0)	0 (0)	0 (0)
Fecal incontinence	65	62 (95.4)	2 (3.1)	1 (1.5)	0 (0)	0 (0)
Rectal fistula	65	65 (100)	0 (0)	0 (0)	0 (0)	0 (0)